Metabolic
Dual GIP/GLP-1 receptor agonist for diabetes and chronic weight management
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, dyslipidemia, or cardiovascular disease.
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It simultaneously activates both GIP and GLP-1 receptors, providing complementary mechanisms for blood sugar control and weight reduction. This dual action enhances insulin secretion, reduces glucagon levels, slows gastric emptying, and reduces appetite.
Administered as a subcutaneous injection once weekly. Treatment starts at 2.5 mg weekly for 4 weeks, then increased to 5 mg weekly. Further dose escalation to 7.5 mg, 10 mg, 12.5 mg, or 15 mg may be considered based on response.